Skip to content
type1.science
Phase 2Not yet recruitingNCT07616206

Cadisegliatin as an adjunct for hybrid closed-loop users

vTv Therapeutics phase 2a randomized crossover study testing cadisegliatin (TTP399) versus placebo as an adjunct to insulin in adults with type 1 diabetes using hybrid closed-loop systems.

Primary endpoints

  • Change in time-in-range during the last 2 weeks of each 6-week treatment period

Results so far

No results posted yet.